124 related articles for article (PubMed ID: 33197050)
1. Increase in neuropeptide Y activity impairs social behaviour in association with glutamatergic dysregulation in diabetic mice.
Ueda D; Yonemochi N; Kamata T; Shibasaki M; Kamei J; Waddington JL; Ikeda H
Br J Pharmacol; 2021 Feb; 178(3):726-740. PubMed ID: 33197050
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y and glutamatergic mechanisms in the amygdala and ventral hippocampus differentially mediate impaired social behavior in diabetic mice.
Ueda D; Yonemochi N; Kamata T; Kamei J; Waddington JL; Ikeda H
Behav Brain Res; 2021 May; 405():113195. PubMed ID: 33617904
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of peripheral NPY Y1 and Y2 receptors ameliorates the aberrant baroreceptor reflex sensitivity in streptozotocin induced diabetic rats.
Niu HF; Xu L; Yan Y; Xie F; Yang BF; Ai J
Sheng Li Xue Bao; 2013 Aug; 65(4):370-80. PubMed ID: 23963068
[TBL] [Abstract][Full Text] [Related]
4. Blockage of peripheral NPY Y1 and Y2 receptors modulates barorefex sensitivity of diabetic rats.
Liu J; Wang N; Xie F; Sun LH; Chen QX; Ye JH; Cai BZ; Yang BF; Ai J
Cell Physiol Biochem; 2013; 31(2-3):421-31. PubMed ID: 23548582
[TBL] [Abstract][Full Text] [Related]
5. Lateral septal infusions of the neuropeptide Y Y2 receptor agonist, NPY(13-36) differentially affect different defensive behaviors in male, Long Evans rats.
Trent NL; Menard JL
Physiol Behav; 2013 Feb; 110-111():20-9. PubMed ID: 23274501
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the involvement of neuropeptide Y in the antidepressant effect of imipramine in type 2 diabetes.
Nakhate KT; Yedke SU; Bharne AP; Subhedar NK; Kokare DM
Brain Res; 2016 Sep; 1646():1-11. PubMed ID: 27208493
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide-Y concentration in microdissected hypothalamic regions and in vitro release from the medial basal hypothalamus-preoptic area of streptozotocin-diabetic rats with and without insulin substitution therapy.
Sahu A; Sninsky CA; Kalra PS; Kalra SP
Endocrinology; 1990 Jan; 126(1):192-8. PubMed ID: 2136723
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: Interaction with glutamatergic functions.
Ikeda H; Ikegami M; Kai M; Kamei J
Exp Neurol; 2015 Jul; 269():233-41. PubMed ID: 25929688
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis of hypothalamic and pituitary components of the growth hormone axis in fasted and streptozotocin-treated neuropeptide Y (NPY)-intact (NPY+/+) and NPY-knockout (NPY-/-) mice.
Park S; Peng XD; Frohman LA; Kineman RD
Neuroendocrinology; 2005; 81(6):360-71. PubMed ID: 16244497
[TBL] [Abstract][Full Text] [Related]
10. Reduced NPY induced feeding in diabetic but not steroid-treated rats: lack of evidence for changes in receptor number or affinity.
Morgan DG; Lambert PD; Smith DM; Wilding JP; Bloom SR
J Neuroendocrinol; 1996 Apr; 8(4):283-90. PubMed ID: 8861284
[TBL] [Abstract][Full Text] [Related]
11. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y inhibits double peaked vasoconstrictor responses to periarterial nerve stimulation primarily through prejunctional Y2 receptor subtype in canine splenic arteries.
Yang XP; Chiba S
Auton Autacoid Pharmacol; 2002 Apr; 22(2):119-26. PubMed ID: 12568129
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of diabetic hyperphagia in neuropeptide Y--deficient mice.
Sindelar DK; Mystkowski P; Marsh DJ; Palmiter RD; Schwartz MW
Diabetes; 2002 Mar; 51(3):778-83. PubMed ID: 11872679
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
15. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors.
El Bahh B; Balosso S; Hamilton T; Herzog H; Beck-Sickinger AG; Sperk G; Gehlert DR; Vezzani A; Colmers WF
Eur J Neurosci; 2005 Sep; 22(6):1417-30. PubMed ID: 16190896
[TBL] [Abstract][Full Text] [Related]
16. Increased endogenous noradrenaline and neuropeptide Y release from the hypothalamus of streptozotocin diabetic rats.
Morris MJ; Pavia JM
Brain Res; 2004 Apr; 1006(1):100-6. PubMed ID: 15047028
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.
Gibbs JL; Diogenes A; Hargreaves KM
Br J Pharmacol; 2007 Jan; 150(1):72-9. PubMed ID: 17143304
[TBL] [Abstract][Full Text] [Related]
18. Acupuncture decreases neuropeptide Y expression in the hypothalamus of rats with Streptozotocin-induced diabetes.
Lee JD; Jang MH; Kim EH; Kim CJ
Acupunct Electrother Res; 2004; 29(1-2):73-82. PubMed ID: 15382790
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization.
Koulu M; Movafagh S; Tuohimaa J; Jaakkola U; Kallio J; Pesonen U; Geng Y; Karvonen MK; Vainio-Jylhä E; Pöllönen M; Kaipio-Salmi K; Seppälä H; Lee EW; Higgins RD; Zukowska Z
Ann Med; 2004; 36(3):232-40. PubMed ID: 15181979
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system.
Hökfelt T; Broberger C; Zhang X; Diez M; Kopp J; Xu Z; Landry M; Bao L; Schalling M; Koistinaho J; DeArmond SJ; Prusiner S; Gong J; Walsh JH
Brain Res Brain Res Rev; 1998 May; 26(2-3):154-66. PubMed ID: 9651513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
